Changing the treatment of permanent neonatal diabetes mellitus from insulin to glibenclamide in a 4-month-old infant with KCNJ11 activating mutation

Permanent neonatal diabetes mellitus (pndm) is a rare type of diabetes and kcnj11 gene activating mutation is one of its prevalent causes. we introduced a 4-month-old male infant with poor feeding,restlessness,tachypnea,hyperglycemia,metabolic acidosis,and ketonemia. he was discharged with insulin and after 2 months,kcnj11 gene mutation was found and treatment was switched from subcutaneous insulin to oral glibenclamide. now,he is 1 year old with desirable glycemic control; therefore,genetic study is recommended for kcnj11 gene mutation in such patients because if the mutation is found,treatment can be switched from insulin to sulfonylurea.